Safety and immunogenicity of an intramuscular pandemic influenza vaccine [influenza A virus vaccine-H5N1] in adults and the elderly
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2014
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Sanofi
- 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2008 Planned end date added as 1 Jun 2009 as reported by ClinicalTrials.gov.
- 15 Jan 2007 New trial record.